DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers

Abstract

In the present study the DNA cell content of 205 de novo acute myeloblastic leukemia (AML) patients is analyzed at flow cytometry in order to determine both the incidence of DNA aneuploidy in A M 1 patients and the clinical and biological characteristics of AML aneuploid cases. All technical procedures were performed in accordance with the proposed guidelines of the DNA Cytometric Consensus Conference. Our results show that the incidence of DNA aneuploidy is quite low (4.8%), with most cases (n = 8) hyperdiploid and only a small proportion (n = 2) hypodiploid. No major differences were detected between the aneuploid and diploid cases with respect to the clinical and prognostic disease characteristics. Regarding the immunophenotype of the blast cells, the aneuploid cases displayed both a higher incidence of immature myeloblastic phenotype and a greater expression of lymphoid-associated antigens. In summary, our results show that A M 1 patients display a quite low incidence of DNA aneuploidy and that despite the fact that these cases do not display particular clinical characteristics, they show an association with the expression of lymphoid-related markers. o 1995 Why-Liss, Inc.

Fcγ Receptor Cross-linking Stimulates Cell Proliferation of Macrophages via the ERK Pathway

“…Therefore, Fc␥R is used as a marker for leukemia typing of M4 and M5 (71,72). The high proliferation rate of leukemic cells is considered an unfavorable prognostic factor because AML patients with a high number of S-phase cells have shorter survival (73). Conceivably, Fc␥R is not just a marker for AML typing but could also function as an amplifier for the growth of leukemic cells in the presence of antibody cross-linking.…”

DNA image cytometry in MDS bone marrow smears

“…Cytometric quantitation of the nuclear DNA content is done mainly by the use of two methods, flow (FCM) or image (ICM) cytometry. However, the most frequent method used in haematological material, by means of the nuclear DNA content, is still FCM (Barlogie et al, 1987;Montecucco et al, 1983;Clark et al, 1986;Peters et al, 1986;Hoy et al, 1989;Hiddemann et al, 1986;Look et al, 1985;Alanen et al, 1993;Parikh et al, 1995;Vidriales et al, 1995;Kamihira et al, 1994), which makes the results difficult to interprete due to an average of all lineages and maturation stages in the bone marrow. In contrast, ICM enables studies of intact single subpopulations of cells selected by morphology, both for prospective as well as for retrospective purpose (Auffermann et al, 1988;Bauer et al, 1990;Kropff et al, 1991;Muller et al, 1991;Widell et al, 1993c;Czader et al, 1993).…”

Significance of numerical chromosome abnormalities in children with acute leukaemias detected by flow cytometry

“…Generally, no prognostic relation of MN and patient outcome was detected in paediatric AMLs [45]. Analysis of a large series of de novo AML indicated a higher incidence of immature myeloblastic phenotype in aneuploid patients and high incidence of expression of CD4, TdT, CD19, and CD7 on leukaemic blasts with respect to diploid cases [49]. So far, there are no data on the association of aneuploidy with any specific immunophenotype or prognosis in AML patients.…”